Concepts (120)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parathyroid Hormone | 5 | 2008 | 23 | 0.270 |
Why?
|
| Parathyroidectomy | 4 | 2008 | 11 | 0.220 |
Why?
|
| Hyperparathyroidism | 4 | 2004 | 5 | 0.200 |
Why?
|
| Famotidine | 1 | 2001 | 1 | 0.170 |
Why?
|
| Histamine H2 Antagonists | 1 | 2001 | 6 | 0.170 |
Why?
|
| Autistic Disorder | 1 | 2001 | 38 | 0.170 |
Why?
|
| Laboratories | 2 | 1989 | 9 | 0.150 |
Why?
|
| Medical Laboratory Science | 2 | 1989 | 9 | 0.150 |
Why?
|
| Brain | 1 | 2001 | 1200 | 0.100 |
Why?
|
| Monitoring, Intraoperative | 3 | 2008 | 36 | 0.100 |
Why?
|
| Graft Survival | 2 | 2008 | 84 | 0.090 |
Why?
|
| Clinical Laboratory Information Systems | 1 | 1989 | 1 | 0.080 |
Why?
|
| Information Systems | 1 | 1989 | 15 | 0.080 |
Why?
|
| Robotics | 1 | 1989 | 20 | 0.080 |
Why?
|
| Equipment and Supplies, Hospital | 1 | 1988 | 1 | 0.070 |
Why?
|
| Blood Specimen Collection | 1 | 2008 | 5 | 0.070 |
Why?
|
| Laboratories, Hospital | 1 | 1988 | 3 | 0.070 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2008 | 6 | 0.070 |
Why?
|
| Transplantation Tolerance | 1 | 2008 | 4 | 0.070 |
Why?
|
| Gelatinases | 1 | 2008 | 3 | 0.070 |
Why?
|
| Chemotaxis | 1 | 2008 | 5 | 0.070 |
Why?
|
| Skin Transplantation | 1 | 2008 | 12 | 0.070 |
Why?
|
| Heart Transplantation | 1 | 2008 | 29 | 0.070 |
Why?
|
| ADAM Proteins | 1 | 2008 | 37 | 0.070 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2008 | 30 | 0.070 |
Why?
|
| Graft Rejection | 1 | 2008 | 61 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 95 | 0.070 |
Why?
|
| Physicians' Offices | 1 | 1987 | 6 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2008 | 94 | 0.070 |
Why?
|
| Health Facilities | 1 | 1987 | 26 | 0.070 |
Why?
|
| Clinical Laboratory Techniques | 1 | 1987 | 27 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2008 | 109 | 0.070 |
Why?
|
| Calcium | 3 | 2003 | 358 | 0.060 |
Why?
|
| Parathyroid Glands | 1 | 2004 | 8 | 0.060 |
Why?
|
| Male | 10 | 2008 | 12629 | 0.050 |
Why?
|
| Child | 4 | 2003 | 1171 | 0.050 |
Why?
|
| Body Weight | 2 | 2001 | 129 | 0.050 |
Why?
|
| Receptors, Histamine H2 | 1 | 2001 | 1 | 0.040 |
Why?
|
| Histamine | 1 | 2001 | 7 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2008 | 2988 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2001 | 324 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2001 | 382 | 0.040 |
Why?
|
| Research Design | 1 | 2001 | 157 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2001 | 380 | 0.040 |
Why?
|
| United States | 3 | 1989 | 1829 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 1 | 1999 | 31 | 0.040 |
Why?
|
| Troponin I | 1 | 1999 | 11 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2001 | 578 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 1999 | 124 | 0.030 |
Why?
|
| Humans | 11 | 2008 | 23331 | 0.030 |
Why?
|
| Cytokines | 2 | 2008 | 213 | 0.030 |
Why?
|
| Creatine Kinase | 1 | 1977 | 19 | 0.030 |
Why?
|
| Middle Aged | 6 | 2008 | 8055 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 2 | 2008 | 28 | 0.030 |
Why?
|
| Adult | 6 | 2008 | 7070 | 0.030 |
Why?
|
| Mice | 2 | 2008 | 1236 | 0.030 |
Why?
|
| Female | 7 | 2008 | 13124 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2008 | 452 | 0.020 |
Why?
|
| Aged | 4 | 2008 | 7552 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2008 | 1523 | 0.020 |
Why?
|
| Adolescent | 4 | 2003 | 1916 | 0.020 |
Why?
|
| Antipyrine | 1 | 1991 | 1 | 0.020 |
Why?
|
| Sexual Maturation | 1 | 1991 | 2 | 0.020 |
Why?
|
| Testosterone | 1 | 1991 | 27 | 0.020 |
Why?
|
| Animals | 2 | 2008 | 3287 | 0.020 |
Why?
|
| Estradiol | 1 | 1991 | 51 | 0.020 |
Why?
|
| Saliva | 1 | 1991 | 48 | 0.020 |
Why?
|
| Aged, 80 and over | 3 | 2003 | 3783 | 0.020 |
Why?
|
| Autoanalysis | 1 | 1989 | 2 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2003 | 594 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 73 | 0.020 |
Why?
|
| Dipeptides | 1 | 2008 | 2 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2008 | 19 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2008 | 28 | 0.020 |
Why?
|
| Protease Inhibitors | 1 | 2008 | 6 | 0.020 |
Why?
|
| Chemokines | 1 | 2008 | 17 | 0.020 |
Why?
|
| Doxycycline | 1 | 2008 | 15 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 96 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2008 | 50 | 0.020 |
Why?
|
| Collagen | 1 | 2008 | 79 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 46 | 0.020 |
Why?
|
| Chemistry Techniques, Analytical | 1 | 1987 | 1 | 0.020 |
Why?
|
| Hematologic Tests | 1 | 1987 | 6 | 0.020 |
Why?
|
| Skin | 1 | 2008 | 119 | 0.020 |
Why?
|
| Equipment Design | 1 | 1987 | 123 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2008 | 360 | 0.020 |
Why?
|
| Decision Making | 1 | 1988 | 187 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2008 | 293 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2004 | 19 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2008 | 1441 | 0.010 |
Why?
|
| Patient Selection | 1 | 2004 | 171 | 0.010 |
Why?
|
| Intraoperative Care | 1 | 2003 | 41 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2003 | 442 | 0.010 |
Why?
|
| Immunoradiometric Assay | 1 | 2001 | 2 | 0.010 |
Why?
|
| Parathyroid Neoplasms | 1 | 2001 | 5 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 2001 | 23 | 0.010 |
Why?
|
| Frozen Sections | 1 | 2001 | 14 | 0.010 |
Why?
|
| Isoenzymes | 2 | 1980 | 50 | 0.010 |
Why?
|
| Adenoma | 1 | 2001 | 61 | 0.010 |
Why?
|
| Muscular Dystrophies | 1 | 1980 | 2 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1980 | 6 | 0.010 |
Why?
|
| Muscles | 1 | 1980 | 56 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2000 | 243 | 0.010 |
Why?
|
| ROC Curve | 1 | 1999 | 125 | 0.010 |
Why?
|
| Aqueous Humor | 1 | 1978 | 1 | 0.010 |
Why?
|
| Retinoblastoma | 1 | 1978 | 1 | 0.010 |
Why?
|
| Catecholamines | 1 | 1978 | 7 | 0.010 |
Why?
|
| Eye Neoplasms | 1 | 1978 | 5 | 0.010 |
Why?
|
| Reoperation | 1 | 2001 | 776 | 0.010 |
Why?
|
| Brain Injuries | 1 | 1977 | 30 | 0.010 |
Why?
|
| Body Surface Area | 1 | 1991 | 3 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1991 | 5 | 0.010 |
Why?
|
| Puberty | 1 | 1991 | 11 | 0.010 |
Why?
|
| Age Factors | 1 | 1991 | 641 | 0.000 |
Why?
|
| Time Factors | 1 | 1991 | 1289 | 0.000 |
Why?
|
| Genetic Carrier Screening | 1 | 1980 | 10 | 0.000 |
Why?
|
| Metanephrine | 1 | 1978 | 1 | 0.000 |
Why?
|
| Methoxyhydroxyphenylglycol | 1 | 1978 | 1 | 0.000 |
Why?
|
| Normetanephrine | 1 | 1978 | 1 | 0.000 |
Why?
|
| Vanilmandelic Acid | 1 | 1978 | 1 | 0.000 |
Why?
|